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“People need to be more compassionate. Chronic pain is no joke. And it’s every day waking up 
not knowing how you’re going to feel.” 
Lady Gaga 
 
“Vive-se com a necessidade constante de justificar que, não é preguiça, é doença e ao mesmo tempo, ter 
a habilidade de não justificar tudo com ela, porque, ainda que seja a verdade, pode ser mal interpretado, 
como desculpa para a preguiça.”  
Sónia Tavares, The Gift 
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Resumo 
 
Introdução: A fibromialgia é uma doença caracterizada por dor generalizada, fadiga, distúrbios de sono e 
problemas psicológicos e de cognição. A doença afeta maioritariamente o sexo feminino, na meia idade, 
sendo a sua prevalência de 1,7% em Portugal. Atualmente não existe cura e o tratamento da doença é 
realizado com base nos sintomas, sendo constituído por tratamento farmacológico e não farmacológico. 
A fibromialgia é de especial relevância no quotidiano do doente, e pode afetar a sua qualidade de vida 
negativamente. Objetivos: Caracterizar a farmacoterapia do doente português com fibromialgia, 
analisando a sua satisfação no que toca à medicação; e avaliar o impacto desta na condição de saúde e 
capacidade funcional do doente. Metodologia: Foi realizado um estudo observacional, onde foi aplicado 
um questionário online, à população portuguesa, através de associações portuguesas. Foi constituído por 
quatro partes: caracterização sociodemográfica; Fibromyalgia Impact Questionnaire; caracterização 
farmacoterapêutica e o Treatment Satisfaction Questionnaire for Medication. Os dados obtidos foram 
analisados estatisticamente e as variáveis foram relacionadas através de teste de ANOVA e correlação 
de Pearson. Resultados: A amostra apresentou um score de 64,89 ± 15,92 no Fibromyalgia Impact 
Questionnaire, que se evidenciou relacionado com a idade e a zona de residência (p = 0,039 e p = 0,047 
respetivamente). Os grupos de fármacos mais comumente utilizados pelos doentes foram: anti-
inflamatórios não esteróides (17,7%) e ansiolíticos (16,9%).  Relativamente à satisfação com a medicação, 
os doentes evidenciaram um score de 67,87 na “Conveniência”, 67,59 nos “Efeitos Adversos”, 45,01 na 
“Eficácia” e 46,25 na “Satisfação Global”.  Esta mostrou-se influenciada pelo tempo de diagnóstico, 
número de medicamentos administrados e pela natureza da medicação. Discussão e Conclusão: Os 
resultados do score do Fibromyalgia Impact Questionnaire evidenciam que a doença tem um impacto 
negativo na vida doente, uma vez que o score apresenta um valor superior a 50. Os doentes com 
fibromialgia tendem a tomar mais que uma medicação, e os grupos farmacoterapêuticos dos anti-
inflamatórios não esteróides e ansiolíticos são os mais usados, no entanto são também os menos 
aconselhados na literatura devido à falta de eficácia e/ou efeitos secundários. Também várias classes de 
antidepressivos e anticonvulsivantes são grupos usados para o tratamento da fibromialgia, que apesar de 
eficazes, não representam os grupos de maior consumo. Relativamente à satisfação com a medicação, os 
valores devem ser avaliados cuidadosamente devido à diversidade do tratamento. A fibromialgia tem um 
impacto negativo na qualidade de vida, e neste sentido são necessários mais estudos que explorem 
terapias eficazes na fibromialgia, com efeitos adversos mínimos, de forma a garantir a adesão ao 
tratamento, melhorando a qualidade de vida do doente.  
 
 
Palavras-chave: Fibromialgia; Dor Crónica; Treatment Satisfaction Questionnaire for Medication; 
Fibromyalgia Impact Questionnaire  
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Abstract 
 
Introduction: Fibromyalgia is characterized by widespread pain, fatigue, sleep disturbance, and 
psychological and cognitive problems. The disease affects mainly females in middle age and has a 
prevalence of 1,7% in Portugal. The treatment is based on experienced symptoms and consists in 
pharmacological and non-pharmacological treatment. Fibromyalgia has an important impact on patient's 
life and can negatively affect their quality of life. Objectives: Characterize the patient's pharmacotherapy 
and analyse their satisfaction with medication and understand if this affects patient's health condition and 
functional capacity. Methodology: An observational study was made with the application of an online 
questionnaire to the Portuguese population, through portuguese associations. It was composed by four 
parts: sociodemographic characterization; Fibromyalgia Impact Questionnaire; pharmacotherapeutic 
characterization and the Treatment Satisfaction Questionnaire for Medication The data obtained were 
statistically analysed and the variables were related trough ANOVA and Pearson correlation. Results: The 
population presented a score of 64,89 ± 15,92 in the Fibromyalgia Impact Questionnaire, and this was 
associated with age and the area of residence (p = 0,039 and p = 0,047). The most common medication 
among patients were the non-steroidal anti-inflammatory group (17,7%) and anxiolytics drugs (16,9%). 
Regarding the Treatment Satisfaction Questionnaire, the score was 67,87 for “Convenience”, 67,59 for 
“Adverse Effects”, 45,01 for “Effectiveness” and 46,25 for “Global Satisfaction” and was influenced by time 
of diagnosis, number of medications taken and by the drug classes.  Discussion and Conclusion: From the 
average Fibromyalgia Impact Questionnaire score, it can be observed that the disease has a negative 
impact on life, since the score is greater than 50. Patients with fibromyalgia tend to take more than one 
medication: non-steroidal anti-inflammatory and anxiolytic groups are the most commonly used, 
however they are also the least advised due to lack of efficacy and/or side effects. In addition, 
antidepressants and anticonvulsants, despite being recommend in fibromyalgia patients, they are not very 
common drugs in this sample. The Treatment Satisfaction values should be carefully evaluated due to the 
diversity of treatment. Further research is needed to unravel effective therapies that can ameliorating the 
various symptoms of fibromyalgia with minimal adverse effects, in order to ensure treatment adherence 
and further improve patient’s quality of life.  
 
 
 
 
 
Key-Words: Fibromyalgia; Chronic Pain; Treatment Satisfaction Questionnaire for Medication; 
Fibromyalgia Impact Questionnaire 
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1. Introduction 
Fibromyalgia (FM) is a chronic disease characterized by widespread musculoskeletal pain, 
associated with sleep disorders and fatigue. FM is also following for emotional changes and 
decreased quality of life (Rosado, et al., 2006; Wiffen Philip et al., 2013).  
Fibromyalgia replaced the previous term “fibrositis”, in the 1980s after exhaustive efforts to prove 
the existence of inflammatory or other abnormalities of muscle and connective tissue had failed 
(Hawkins, 2013). 
The pathophysiology of FM is not completely recognized. However, is pathogenesis and etiology are 
known to be multifactorial (Yunus & İnanici, 2001). The most accepted theory is related to the state 
of centralized pain, which amplifies the pain creating an abnormal response to different stimuli 
(Clauw, 2014; Tzellos et al., 2010). 
FM diagnosis is based in the criteria of the American College of Rheumatology (ACR) of 2010. 
Rheumatologists are the indicated to make the diagnosis and prescribe the necessary treatment to 
the patient (Dymon et al., 2015). The management must be composed by pharmacological and non-
pharmacological therapies. Once the FM don’t have any cure, the treatment needs to be based on 
the symptoms.  
1.1 Epidemiology 
Results from the prevalence of FM between 1990 and 2005, varied from 0,7 to 4,4%. Marques et al, 
shows, on their literature update, the prevalence between 2005 and 2014 ranged from 0,2 and 6,6% 
after 39 studies were analyzed (Marques et al., 2017). In 2013, Queiroz mentioned in his paper that 
the global prevalence of FM, in 26 studies worldwide, is 2,7% (Queiroz, 2013). 
A literature review of 2017 shows the lowest results in Venezuela (0,2%) and the highest in United 
States of America (USA) (6,4%), using the ACR criteria. Meanwhile in Europe the prevalence is 2,5% 
(Marques et al., 2017; Queiroz, 2013). A prevalence study of 2010, made in five different countries of 
Europe (France, Italy, Germany, Spain and Portugal), shows a point prevalence of FM in Portugal of 
3,6%, using The London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ) 
(Branco et al., 2010). According to the Portuguese Health Agency - Direção Geral de Saúde (DGS), 
1,7% of the Portuguese population is affected with FM (Direção-Geral da Saúde, 2017). 
Many surveys show a higher prevalence on the female population. In the review of Marques et al, 
the prevalence of the disease was between 2,4% and 6,8% (Marques et al., 2017). Queiroz, et al, 
indicates a 4,2% prevalence in female and 1,4% in male, with a 3:1 ratio (Queiroz, 2013). 
Studies also show a higher occurrence of FM in the middle age or after 50 years, low educated 
individuals, obese women and who live in rural areas (Marques et al., 2017; Queiroz, 2013) 
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1.2 Etiology and Pathofisiology 
Since the first description of FM in 1981 many researches and studies have been published clarifying 
the etiology and pathophysiology of the disease. FM is heterogeneous and explained by different 
hypotheses. Is believed that factors as genetic, sleep disorders, infections, stress factors, both 
physical or emotional can contribute to FM’s pathophysiology (Clauw, 2014). 
 Is known that the pathogenesis of this disease is related to a dysregulation in the reception of 
nociceptive stimuli by the central nervous system (CNS) (Pillmer et al., 1997). 
1.2.1 Central Sensitization  
Patients with FM present hyperalgesia, an increased response to a painful stimulus as well as 
allodynia, pain caused by a stimulus that normally does not cause pain like touching or rubbing. 
Studies shown that patients with FM are sensible to any type of stimuli such as heat, cold, electrical 
stimuli, the brightness of a light or the loudness of tones (Schmidt-Wilcke & Clauw, 2011). 
FM is related to central sensitization (Clauw, 2014; Yunus & İnanici, 2001). Central sensitization is 
defined as a hyperexcitability of the CNS neurons in response to a peripheral nociceptive stimulus 
leading to an exaggerated response to a normal painful stimulus (hyperalgesia) or a normal painless 
stimulus (allodynia) (Yunus & İnanici, 2001). 
When a stimulus is caused in the skin or muscles, the coursing is made till the periphery to the dorsal 
horn via C-fibers (primary afferent fibers) and to the brain via the spinothalamic tract (Bradley, 2009; 
Yunus & İnanici, 2001).  In the dorsal horn, pain transmission can be modulated by the activation of 
descending pain inhibitory pathways, which include serotonin and norepinephrine/noradrenaline 
(Bradley, 2009; Yunus & İnanici, 2001). 
In the cortex, primary afferents transmit action potentials to presynaptic terminals where the 
substance P (SP) and glutamate (excitatory aminoacid) are released, these bind to pain transmission 
neurons (PTN)  such as amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA); N-
methyl-D-aspartic acid (NMDA) and neurokinin (NK-1) (Bradley, 2009; Yunus & İnanici, 2001). 
In FM patients, the PTN became sensitized when there’s an exposure to a painful stimulus. An influx 
of Ca2+ increases nitric oxide (NO) which causes PTNs to be hyperexcitable, who leads to augmented 
release of SP and excitatory aminoacids. Glia cells are also involved in this mechanism, being 
activated and releasing substances (e.g., nitric oxide, reactive oxygen species, prostaglandins, 
proinflammatory cytokines, nerve growth factor) increase presynaptic release and cause post 
synaptic hyperexcitability (Figure 1) (Bradley, 2009; Yunus & İnanici, 2001).. 
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Russel et al., indicate that serotonin and noradrenaline, both involved in descending pain inhibitory 
pathways, are decreased in FM patients. Russel et al. found low levels of these neurotransmitters 
on blood serum and also low levels of their metabolites on cerebrospinal fluid (Russell et al., 1994).  
SP, an important nociceptive transmitter, has also an important role in pain transmission. Studies 
measure SP in cerebrospinal fluid indicates that is three times higher in FM patients compared to 
healthy patients (Yunus & İnanici, 2001). 
The NMDA, involved in the central sensitization mechanism, in specific their receptors (NMDAR) 
where the glutamate binds, as an important role in the pathophysiology of the pain. A double-blind 
placebo controlled test, indicates a reduction of pain intensity when ketamine, a non-competitive 
NMDAR antagonist, was administrated as compared with a isotonic saline (Yunus & İnanici, 2001). 
Cagnie et al., indicated that exists several changes in the brain of individuals of FM, such as decrease 
in gray matter volume in regions associated to pain processing and stress (Cagnie et al., 2014). 
 
 
Figure 1 - Pain Perception (Adapted Bradley, 2009) 
1.2.2 Genetic 
Harte et al, indicates that serotonin 5-HT2A receptor polymorphism T/T phenotype, serotonin 
transporter, dopamine 4 receptor and catecholamine o-methyl transferase (COMT) polymorphism 
have a higher frequency in FM patients then controls (Harte, Harris, & Clauw, 2002; Neumann & 
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Buskila, 2003). There is also a 8,5 bigger probability that first degree relatives develop the disease 
in comparation to the normal population (Hawkins, 2013). 
1.2.3 Sleep disorders 
Sleep problems such as insomnia, poor sleep quality or non-restorative sleep are usual in FM. 
There’s evidence that a poor night of sleep can contribute to worsening the symptoms, causing 
painful days and painful days can cause a poor night of sleep, turning into a vicious cycle (Pillemer et 
al., 1997). 
Polysomnographic studies show the existence of alpha activity during non-REM sleep on 
electroencephalograms (EEG) of patients with FM. This activity is associated with decreased 
production of growth hormone (GH) and insulin-like growth factor type-1 (IGF-1), required for 
physiological repair (Bradley, 2009). 
This suggested that treating sleep disorders may be essential to improve FM symptomatology 
(Pillemer et al., 1997; Yunus & İnanici, 2001). 
1.2.4 Psychological Stressors 
Depression, anxiety, bipolar, post-traumatic stress, and obsessive-compulsive disorders are 
common psychiatric syndromes in patients with FM (Hawkins, 2013; Sancassiani et al., 2017; 
Schmidt-Wilcke & Clauw, 2011). 
There is a relationship between pain and distress, who can be a cause or consequence of pain. When 
presented as a consequence, it may cause problems to the patient which may increase their 
symptoms leading to isolation, difficulty in coping and decreased activity (Schmidt-Wilcke & Clauw, 
2011). 
Studies have revealed a prevalence of major depression in 26% of 31 FM patients compared with 
none of 14 rheumatoid arthritis (RA) patients and onset of depression occurred in 64% after FM 
diagnosis (Yunus & İnanici, 2001). In a multicenter study was found that FM patients had high levels 
of major depression and panic disorder. However it’s hard to predict who came first due to the 
difficult of the accuracy of the begging of the symptoms in FM (Epstein et al., 1999). 
Childhood abuse is also related to FM, a meta analyses shows that people who suffered abuse or 
where neglected have more pains symptoms compared to others (Sancassiani et al., 2017). 
Furthermore, past traumatic events such as car accidents, death of a relative or hospitalizations can 
also increase the risk of developing generalized pain (Hawkins, 2013; Schmidt-Wilcke & Clauw, 
2011). 
The hypothalamic-pituitary-adrenal (HPA) axis can also be associated to FM, once emotional and 
physical stress can activate him (Schmidt-Wilcke & Clauw, 2011). 
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1.2.5 Infections and other mecanisms 
Biological stressors can also be a trigger to the development of FM. It has been shown that 5 -10% 
of individuals exposed to viral or bacterial infections such as Lyme's disease, Epstein-Barr virus, 
parvovirus, Q fever, hepatitis B and C can develop generalized pain (Schmidt-Wilcke & Clauw, 2011). 
Also, autoimmune diseases such as RA, lupus erythematosus or physical trauma may be the cause 
of central sensitization. Inflammatory states are involved in central sensitization, a theory 
corroborated for the appearance of FM followed after inflammatory diseases, who proves the 
inflammation can be the source of central sensitization (Clauw, 2014; Hawkins, 2013; Yunus & İnanici, 2001). 
Some studies refer to a deficiency of vitamin D is also related to chronic pain and FM, directing 
therapy with this vitamin can improve symptoms of the disease. However, these studies are few 
and inconclusive (Chinn et al., 2016) 
1.3 Clinical Condition 
The main symptom of FM patients is pain: a generalized chronic pain. Symptoms of the disease also 
include fatigue, depression, sleep disturbance, anxiety, stiffness, headache and cognitive 
impairment. About 60-70% of patients complain of "hurt all over". The most common locations of 
this pain are neck, lower back, hands, knees, shoulders, arms, elbows, hips and feet (Yunus & İnanici, 
2001). 
Stiffness is also common in those patients. Stiffness and pain can be potentiated by weather factors, 
trauma, noise, poor sleep or stress (Hawkins, 2013). 
Extreme fatigue, paresthesia, extremity swelling, headache, irritable bowel syndrome, restless leg 
syndrome, primary dysmenorrhea, female urethral syndrome, poor balance, sicca symptoms and 
Raynaud phenomenon are also symptoms present in FM (Yunus & İnanici, 2001). 
Physical exams show swollen knees in patients with FM. There is also limitation of movement in the 
neck and joints due to pain, however they may also be related to the presence of other diseases such 
as osteoarthritis or RA (Yunus & İnanici, 2001). 
 
1.3.1 Diagnostic Criteria 
In 1990, the ACR developed the diagnostic criteria for FM. It defined the disease as a combination of 
the history of generalized pain for more than 3 months and the presence of at least 11 of the 18 tender 
points, digitally palpated with a pressure of approximately 4kg (Figure 2) (Gittins et al., 2017; F Wolfe 
et al., 1990) 
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1. History of Widespread Pain 
Definition. Pain is considered widespread when all of the following are present: pain in the left side of the 
body. pain in the right side of the body, pain above the waist. and pain below the waist. In addition, axial 
skeletal pain (cervical spine or anterior chest or thoracic spine or low back) must be present. In this 
definition. shoulder and buttock pain is considered as pain for each involved side. "Low back" pain is 
considered lower segment pain. 
        2. Pain in 1 1 of 18 tender point sites on digital palpation 
Definition. Pain, on digital palpation, must be present in at least 1 I of the following 18 tender point sites: 
Occiput: bilateral, at the suboccipital muscle insertions.  
Low cervical: bilateral, at the anterior aspects of the intertransverse spaces at C5-C7.  
Trapezius: bilateral. at the midpoint of the upper border.  
Supraspinatus: bilateral, at origins, above the scapula spine near the medial border.  
Second rib: bilateral. at the second costochondral junctions. just lateral to the junctions on upper surfaces.  
Lateral epicondyle: bilateral, 2 cm distal to the epicondyles.  
Gluteal: bilateral, in upper outer quadrants of buttocks in anterior fold of muscle.  
Greater trochanter: bilateral. posterior to the trochanteric prominence.  
Knee: bilateral. at the medial fat pad proximal to the joint line. 
 
Digital palpation should be performed with an approximate force of 4 kg. For a tender point lo be considered 
"positive" the subject must state that the palpation was painful "Tender" is not to be considered “painful”. 
* For classification purposes. patients will be said to have fibromyalgia if both criteria are satisfied. 
Widespread pain must have been present for at least 3 months. The presence of a second clinical disorder 
does not exclude the diagnosis of fibromyalgia. 
 
Figure 2 - The 1990 ACR criteria for the classification of FM* (Wolfe et al.,1990) 
 
However, these criteria show some shortcomings, once fatigue and cognitive problems were not yet 
relevant. On the other hand, the count of tender points can be influenced by the patient-physician 
relationship and may also be related to stress (Clauw, 2014; Frederick Wolfe et al., 2010). 
Due to these problems, the ACR made new criteria in 2010. These eliminated the need for 
examination of tender points and included new symptoms such as fatigue, non-restorative sleep 
and cognitive symptoms (Figure 3) (Frederick Wolfe et al., 2010). 
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Criteria 
 A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are met:  
1) Widespread pain index (WPI) ≥7 and symptom severity (SS) scale score ≥5 or WPI 3–6 and SS scale score ≥9. 
2) Symptoms have been present at a similar level for at least 3 months.  
3) The patient does not have a disorder that would otherwise explain the pain.  
Shoulder girdle, left 
Shoulder girdle, right 
Upper arm, left 
Lower arm, left 
 
Hip (buttock, trochanter), 
left 
Hip (buttock, trochanter), 
right 
Upper leg, left 
Upper arm, right 
Jaw, left 
Jaw, right 
Chest 
Upper leg, right 
Lower leg, left 
Lower leg, right 
Upper back 
Lower back 
Neck 
Abdomen 
Lower arm, right 
 
 
 2) SS scale score:  
Fatigue  
Waking unrefreshed  
Cognitive symptoms  
For the each of the 3 symptoms above, indicate the level of severity over the past week using the following scale: 
0 = no problem  
1 = slight or mild problems, generally mild or intermittent  
2 = moderate, considerable problems, often present and/or at a moderate level  
3 = severe: pervasive, continuous, life-disturbing problems  
 
Considering somatic symptoms in general, indicate whether the patient has*: 
0 = no symptoms  
1 = few symptoms  
2 = a moderate number of symptoms  
3 = a great deal of symptoms 
 
The SS scale score is the sum of the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive 
symptoms) plus the extent (severity) of somatic symptoms in general. The final score is between 0 and 12. 
* Somatic symptoms that might be considered: muscle pain, irritable bowel syndrome, fatigue/tiredness, thinking or remembering 
problem, muscle weakness, headache, pain/cramps in the abdomen, numbness/tingling, dizziness, insomnia, depression, 
constipation, pain in the upper abdomen, nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, 
Raynaud’s phenomenon, hives/welts, ringing in ears, vomiting, heartburn, oral ulcers, loss of/change in taste, seizures, dry eyes, 
shortness of breath, loss of appetite, rash, sun sensitivity, hearing difficulties, easy bruising, hair loss, frequent urination, painful 
urination, and bladder spasms. 
 
Figure 3 - The 2010 ACR criteria for FM (Frederick Wolfe et al.,2010) 
 
The new criteria do not replace the old one but add some previously unrelated criteria such as 
cognitive problems and somatic symptoms. Two variables were added: WPI and SS. WPI is related 
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to tender points and SS allowing to better identify the patient's symptoms. SS used alone allows 
measuring the severity of symptoms such as fatigue, waking unrefreshed cognitive symptoms and 
the somatic symptoms (Frederick Wolfe et al., 2010). 
The new criteria do not require a physical examination of tender points and showed to correctly 
classify 88.1% of the previously cases (Frederick Wolfe et al., 2010). 
However, further testing is required to exclude other syndromes that may be mistaken for FM, such 
as hypothyroidism, inflammation and other myopathies, rheumatic diseases, viral infections, and 
severe vitamin D deficiency (Hawkins, 2013). 
According to the criteria of DGS, the differential diagnosis is composed to complete blood count, 
sedimentation velocity, C-reactive protein, TSH, creatinine phosphokinase and serum calcium 
(Direção-Geral da Saúde, 2017). 
 
1.4 Pharmacological Treatment 
There is great evidence of anomalies in the mediators of serotonin, norepinephrine, SP, glutamate 
and other neurotransmitters when talking about FM. Thus, the pharmacological agents used are 
expected to have as their primary objective a reduction in the activity of neurotransmitters (e.g. 
glutamate) or increasing the activity of pain inhibitors such as serotonin and norepinephrine 
(Hawkins, 2013; Schmidt-Wilcke & Clauw, 2011). 
To date, the Food and Drug Administration (FDA) has approved three FM drugs in the USA: 
pregabalin, duloxetine and milnacipran. In Canada, only pregabalin and duloxetine are approved 
while the European Medicines Agency (EMA) does not have any FM approved drugs. Which means 
that in the European Union, the prescribed medication for FM is off-label	(Chinn et al., 2016).	
Given the various symptoms experienced by patients, it is expected that not only one drug is capable 
of solving the potential symptoms of FM  (Hawkins, 2013). 
1.4.1 Antidepressants 
Tricyclic Antidepressants (TCAs) 
Amitriptyline (ADTÒ) and cyclobenzaprine (FlexibanÒ) are both TCAs with proven effects on FM 
therapy, both showing a 1A level of evidence in the USA (Schmidt-Wilcke & Clauw, 2011). 
Amitriptyline is an inhibitor of serotonin and norepinephrine reuptake, increasing the presynaptic 
concentration of both. According to the European League Against Rheumatism (EULAR) 
amitriptyline reduces pain in 30%, has also a moderate effect on sleep disorders and some effect on 
fatigue. According to this source 25mg/day improves the symptoms described in 6 to 8 weeks. 
50mg/day does not show any benefits due to large rate of drop out because of adverse effects 
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(Goldenberg, Burckhardt, & Crofford, 2004; Kia & Choy, 2017; Macfarlane et al., 2017). On the other 
hand, cyclobenzaprine has a greater effect as a muscle relaxant due to is action mechanism that 
decreases noradrenergic function (Goldenberg et al., 2004; Schmidt-Wilcke & Clauw, 2011). 
 
Serotonin–Noradrenalin Reuptake Inhibitors (SNRI) 
Serotonin and norepinephrine are involved in descending pain inhibitory pathways and therefore 
linked to the pathophysiology of FM. In these patients, the concentration of serotonin and 
tryptophan (serotonin precursor) is in low concentrations both in serum and cerebrospinal fluid (Kia 
& Choy, 2017). 
Duloxetine (CymbaltaÒ) has a greater effect on serotonin, involved in anxiety, depression and 
sleep. EULAR shows that 60mg/day of duloxetine improves depression, anxiety and quality of life, 
not showing substantial effect in lower doses. Duloxetine is both approved by the FDA and Health 
Canada (Calandre et al., 2015). 
Milnacipran (IxelÒ) has a greater effect on noradrenaline, being the analgesia is main effect, 
increasing inhibitory neurotransmission in brain pain modulating mechanisms, with concentrations 
between 100 to 200mg/day. This is one of the three drugs approved for the FDA  (Macfarlane et al., 
2017; Matthey et al., 2013). 
Venlafaxine (EfexorÒ), shows to be helpful in FM patients, regarding to their depression symptoms 
(Epstein et al., 1999).  
 
Selective serotonin reuptake inhibitors (SSRI) 
Drugs such as escitalopram, paroxetine, fluoxetine (ProzacÒ) or sertraline show a moderate 
effect on pain and sleep but no effect on fatigue. A Cochrane review found that there is no benefit 
compared to placebo in the treatment of symptoms but may be beneficial for treating depression in 
patients with FM. Despite being well tolerated, SSRIs do not show superior efficacy (Kia & Choy, 
2017; Macfarlane et al., 2017).  
1.4.2 Anticonvulsants 
Anticonvulsant drugs, pregabalin (LyricaÒ) and gabapentin (NeurontinÒ), act by binding to the 
calcium (Ca2+) channels in CNS, inhibiting the release of neurotransmitters such as glutamate and SP 
in pain pathways, causing an analgesic effect (Kia & Choy, 2017). 
Unlike pregabalin, whose use is approved by the FDA and recommended in guidelines, gabapentin 
presents only one study where it has a beneficial effect on pain (Tzellos et al., 2010). 
Pregabalin was the first FDA approved drug in 2007 for the treatment of FM. Several studies 
confirm its effectiveness in improving pain and sleep, also demonstrating positive results in 
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decreasing the Fibromyalgia Impact Questionnaire (FIQ) score (Kia & Choy, 2017; Macfarlane et al., 
2017; Tzellos et al., 2010). 
The combination of pregabalin with milnacipran has shown beneficial effects on pain, fatigue and 
increased quality of life when compared to placebo. (Tzellos et al., 2010) 
1.4.3 Analgesic Treatments 
Opioid drugs are not recommended for pain management as they may worsen FM symptoms such 
as fatigue and cognition. Although tramadol (TramalÒ) has been shown to be beneficial in relieving 
pain, is use should be considered due to adverse effects and potential abuse (Dymon et al., 2015). 
Nonsteroidal anti-inflammatory drugs (NSAID) do not show a relevant effect on pain given their 
peripheral action (Dymon et al., 2015). 
1.4.4 Cannabinoids  
Cannabinoid drugs have analgesic and beneficial properties in sleep disorders due to their receptors 
on peripheral and central nerves. Moreover, they are related to the regulation of pain perception, 
mood, appetite and memory (Calandre et al., 2015; Kia & Choy, 2017). 
Nabilone, a synthetic cannabinoid that mimics tetrahydrocannabinol (THC), has been studied for 
pain management, showing improvement in FIQ score, anxiety and sleep. However, many 
individuals have dropped out of studies due to adverse effects (Calandre et al., 2015; Chinn et al., 
2016; Kia & Choy, 2017). At the moment, any synthetic cannabinoid is approved in Portugal for the 
management of FM symptoms.  
1.4.5 Others 
Anxiolytic drugs, like alprazolam and other benzodiazepines show positive effects in sleep 
disturbances, however because of their potential dependence is not recommended in long term 
treatments. Also, zolpidem was shown positive effects on sleep and day time energy, but not in pain 
relief (Goldenberg et al., 2004). 
Pramipexole, a dopamine agonist, has been shown to be effective in reducing pain and is 
recommended by EULAR and the Spanish guidelines (Calandre et al., 2015). 
Growth hormone therapy has shown positive effects in some studies, however there is some 
concern about is safety, therefore is not recommended for the treatment of FM (Macfarlane et al., 
2017). 
Studies with narcolepsy-approved, sodium oxybote, have positive effects on pain, sleep and fatigue, 
however, the EMA and FDA do not approve is use due to safety issues. Monoaminoxidase inhibitors 
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(IMAOs), such as pirlindole (ImplementorÒ) have also been studied an showed positive effects, yet 
their interactions are life-threatening (Calandre et al., 2015; Macfarlane et al., 2017). 
1.5 Non-Pharmacological Treatments 
Non-pharmacological therapies can be beneficial in improving quality of life, reducing the severity 
of symptoms or even coping with the disease (Mansoor M. et al 2018; Sim & Adams, 1999).  
The practice of physical exercise has shown to improve the quality of life and also pain. Aerobic 
exercise is shown to have better results, but also flexibility and strength training are beneficial for 
the patient (Chinn et al., 2016; Dymon et al., 2015). 
Cognitive Behavior Therapy (CBT) consists in combination of therapy that helps understand, 
recognize and identify inappropriate behaviors and thoughts with behavioral therapy for a disease 
adaptation (Dymon et al., 2015; Mansoor M. et al., 2018). Patients with FM often show personality 
profiles with high levels of pain and catastrophizing, which further exacerbate pain. CBT develops 
methods such as relaxation, distraction or writing, helping the FM patients create behavioral 
patterns (Mansoor M. et al., 2018). 
Several reviews indicate that practicing yoga, tai chi or qigong can be positive in symptoms such  
sleep and fatigue (Macfarlane et al., 2017). 
Also, mindfulness seems to be useful in developing coping mechanisms. Studies show improvement 
in sleep and symptom severity (Mansoor M. et al., 2018). 
Acupuncture, a traditional Chinese medicine technique, consists in the allocation of thin needles on 
defined body sites, has effect reducing the pain and inflammation, release endorphins and create a 
calmer mind (Mansoor M. et al., 2018). Acupuncture has shown effects on pain, sleep and fatigue 
(Macfarlane et al., 2017). 
1.6 Fibromyalgia and life quality 
Several studies exploring the life quality in FM patients, conclude that the disease conditions lead to 
a drastic decrease in quality of life compared to other groups (Bernard et al.,  2000). 
Disorders involving chronic pain drag to disability in daily life due to both pain and psychological 
problems. The decrease in social support can lead to isolation of the individual that can, in the future, 
interfere with individual, family and social well-being. Restrictions on daily activities such as going 
to work due to FM symptoms may also trigger depression and other mental hilliness in these 
patients (Bernard et al., 2000; Verbunt et al., 2008). 
FM affects physical, psychological, social function and social relationships. Most patients cannot 
fulfil family and work responsibilities and perform daily activities not only due to pain, but also due 
to fatigue, cognitive impairment and others (Galvez-Sánchez et al., 2019). Martins et al., showed that 
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the main influencers of life quality are advanced age, living alone, low level of academic skills and no 
practice of physical exercise. In their sample, 50% of study participants indicate FM as very disabling 
and 45,7% as moderately disabling and FIQ score is 63,76 points, which means reduced quality of 
life (Martins et al., n.d.). 
The life quality of people around is also affected. Social support is compromised, most patients 
report that others cannot understand their disease, thinking they exaggerate their symptoms. Also 
love relationships seem to be compromised: Bernard et al, show in their study that, of the divorced 
participants with FM, 93,9% reported that the cause was disease related (Bernard et al., 2000). 
With regard to sexual health, FM patients have lack of sexual desire, sexual aversion, orgasm 
disorder, vaginismus and dyspareunia which can be related to FM symptoms but also to medication 
side effects or psychological problems. This is an important aspect to solve, because poor sexual life 
can lead to problems in relationships and breakup (Galvez-Sánchez et al., 2019). 
Problems at work are also a reality that patients live due to non-restorative sleep, stress due to work 
and other disease symptoms. Is necessary to readjust the work: since the understanding of 
colleagues, workload and tasks given (Bernard et al., 2000; Galvez-Sánchez et al., 2019). Studies 
show that most patients stopped working after diagnosis and those still working had to cut back on 
their work (Bernard et al., 2000). It was found that when the work schedules were adapted to the 
perception of the abilities of each patient, the patients had shown less exhausted, being able to enjoy 
periods of leisure and greater satisfaction in daily activities (Rosado et al., 2006). 
Emotions such as sadness, fear, anger and guilt are associated with FM patients. Many sufferers 
develop depression, anxiety and other psychological comorbidities that affect the patient’s daily life, 
including enhance symptoms of FM (Galvez-Sánchez et al., 2019). 
Personality disorders are also related to FM, including obsessive compulsive disorder, borderline 
disorder, avoidance disorder. Also, perfectionism, neuroticism and psychoticism are associated with 
FM. The origin is related to psychological stress and readjustment to chronic disease (Galvez-
Sánchez et al., 2019). 
Self-esteem also appears to be affected in patients with FM. It may be linked to low cognitive 
performance in terms of attention or memory. Self-image, the perception, feelings and thoughts 
about the body, are also affected in patients with FM who find their image affected because the 
diagnose (Bernard et al., 2000; Galvez-Sánchez et al., 2019). 
Given the impact of this disease on patient’s quality life, is crucial to evaluate the true influence of 
the pharmacological approaches on FM outcome.     
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1.7 Aims of the study 
The main objective of this study relies on characterizing the pharmacotherapeutic profile and impact 
of FM in a sample of Portuguese patients.  
 
The specific objectives are:  
1) To characterize the pharmacotherapy of the patient with FM; 
a. Identify the main classes of drugs used to treat FM and related it with the 
therapeutic guidelines; 
2) To analyze patient’s perception about the efficacy, tolerance, convenience and global 
satisfaction of the used medication;   
a. Relate the efficacy, tolerance, convenience and global satisfaction with the 
different drugs used to treat FM, the number of used drugs and the diagnosis time.  
3) To understand the health condition and functional capacity of the individual with FM.  
a. Analyze the impact of the disease in different daily life situations; 
b. Relate the impact of FM with age, time of diagnosis and experience of the 
medication 
 
  
 24 
2. Methodology 
This chapter intends to describe the methodology used during the investigation, including 
population and study sample, instruments, statistical analysis and ethical concerns.  
2.1 Study design 
This study was an observational (non-experimental) study, since the investigator collected 
available information from patients without any type of intervention, with  a cross-sectional design, 
since information was collected at a certain point in time, non-defined in the individual’s life (Kumar, 
2014).  
2.2 Population and study sample 
Sample was recruited in Portuguese associations who accompany patients with the fibromyalgia in 
Portugal: National Association Against Fibromyalgia and Chronic Fatigue Syndrome (MYOS), 
Portuguese Association of Young People with Fibromyalgia (APJOF) and Fibromyalgia Association 
(FIBRO) (Attachment 1).  
For the participation in the study, the individuals must had been diagnosed with fibromyalgia, had 
more than 18 years, with Portuguese nationality, be able to read and write, and had access to a 
computer or smartphone with internet connection. 
All the participants were invited to fill an online questionnaire in a voluntarily and anonymously way, 
after reading the informed consent.  
2.3 Instrument of study 
The method for collecting the necessary information was by an online questionnaire helped to 
divulge by MYOS, APJOF and FIBRO. The questionnaire was able online between July 26 and August 
21.  
The used questionnaire was composed by four different parts: 
Socio-demographic Characterization 
The first part was about the socio-demographic characterization of the population (Attachment 2). 
The socio-demographic questionnaire was applied with the purpose of knowing the age, sex, civil 
status, academic degree, work situation and age of the disease diagnosis.  
Fibromyalgia Impact Questionnaire 
In the second part of the questionnaire the Portuguese version of the FIQ was applied (Attachment 
3) (Rosado et al., 2006). The FIQ-P is valid for the Portuguese language and proved to be an 
effective instrument used for health professionals (Rosado et al., 2006). 
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The purpose of FIQ is to determine the impact of the disease in the daily life and the incapacity 
resultant. The higher the score the patient obtains in the FIQ, the greater the impact of the disease 
in the person. The average fibromyalgia patient scores about 50 (Burckhardt, C.S., Clark, S.R, & 
Bennett, 1991). 
The questionnaire is composed for 10 items, when the first item is composed for 11 sub-items. The 
first 11 sub-items measure the functional capacity of the individual or the physical impairment. Each 
item is classified to 4 points, where 0 means "never" and 3 means "always", so the highest score is 
33 (3x11). Because some patients don’t execute all the tasks, they can delete them of the score. For 
a valid summed score, the items the patient has rated are summed and divided by the number of 
items rated (i.e. if the patient completed 8 items at a score of 3 for each, the final score would be 
3x8/8=3) (Burckhardt, C.S., Clark, S.R, & Bennett, 1991). 
The next item, who measure how the patient feels (item 12), is scored inversely: the higher number 
means impairment (i.e., 0=7, 1=6, 2=5, 3=4, 4=3, 5=2, 6=1 and 7=0). The item number 13, who measure 
the missed work days, is scored directly (i.e. 7=7 and 0=0) (Burckhardt, C.S., Clark, S.R, & Bennett, 
1991). 
For the last items (14 to 20), each are scored in 10 increments, so the range is 0 to 10. Those items 
measure the capacity of do work, the pain, the fatigue, the stiffness, anxiety and depression.   
Once the score is done, is necessary to do a normalization procedure so all the scores are expressed 
in the same units. The range of normalized scores is 0 to 10 with 0 indicating no impairment and 10 
indicating maximum impairment. The figure below shows how to normalize the scores of the 10 
items.  
 
Scale  Item #  Recode  Score Range  Normalization  
Physical impairment 1 No 0 -3 S X 3.33 
Feel good 2 Yes 0-7 S X 1.43 
Work missed 3 No 0-7 S X 1.43 
Do work 4 No 0 - 10 None 
Pain 5 No 0 - 10 None 
Fatigue 6 No 0 - 10 None 
Rested 7 No 0 - 10 None 
Stiffness 8 No 0 - 10 None 
Anxiety 9 No 0 - 10 None 
Depression 10 No 0 - 10 None 
Figure 4 - FIQ scores normalization (Burckhardt, C.S., Clark, S.R, & Bennett, 1991) 
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To obtain a score of 100 it necessary to employ the “equalization calculation”. If the patient doesn’t 
answer to all the 10 items the final summative scores needs to be multiplied by 10/x, when x is the 
number of questions missed (e.g if one question is missed: 10/9) (Burckhardt, C.S., Clark, S.R, & 
Bennett, 1991). 
Pharmacotherapeutic Characterization 
The third part of the questionnaire correspond to the pharmacotherapeutic characterization. In this 
part of the questionnaire, the patient informs about the medication used in present and past (if any), 
the reason for discontinuation of a previous treatment and who did the prescription (Attachment 4). 
Treatment Satisfaction Questionnaire 
Four and last part of the questionnaire is applied the Treatment Satisfaction Questionnaire for 
Medication (TSQM) version 1.4 (Attachment 5).  Was applied the translated Portuguese TSQM 
provided by IQVIA (Attachment 6).This questionnaire is a valid instrument to assess patient 
satisfaction with the medication in four ways: side effects, effectiveness, convenience and global 
satisfaction (IQVIA, 2018) 
The TSQM 1.4 consists in 14 items, who corresponds to domains referred above. For each domain is 
necessary a specific calculation to obtain a score range between 0 and 100. The specific calculation 
is presented below: 
 
Global Satisfaction  
([(Sum(Item 12 to Item 14)) – 3] divided by 14) * 100  
If Item 12 or 13 is missing  
[(Sum(the two completed items)) – 2] divided by 10) * 100  
If Item 14 is missing  
([(Sum(Item 12 and Item 13)) – 2] divided by 8) * 100  
 
Effectiveness  
([(Item 1 + Item 2 + Item 3) – 3] divided by 18) * 100  
If one item is missing  
([Sum(the two completed items)) – 2] divided by 12) * 100  
 
Side Effects  
If Question 4 is answered ‘No’ then score = 100  
or 
([Sum(Item 5 to Item 8) – 4] divided by 16) * 100 
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If one item is missing  
([(Sum(the three completed items)) – 3] divided by 12) * 100  
 
Convenience  
([Sum(Item 9 to Item 11) – 3] divided by 18) * 100  
If one item is missing  
([(Sum(the two completed items)) – 2] divided by 12) * 100  (IQVIA, 2018) 
2.4 Statistical Analysis 
For the data’s edition and treatment was used the Statistical Package for the Social Sciences (SPSS) 
version 25 for MacOS.  
Variables can be divided into dependent and independent variables. Independent variables present 
in the socio demographic questionnaire were age, sex, education, residence area, professional and 
civil status and years of diagnosis. Also, the drug-related variables present in the questionnaire of 
pharmacotherapeutic characterization are independent. The study dependent variables were FIQ 
and TSQM. 
To describe the results a descriptive analysis of the nominal and ordinal variables was performed, 
such as the described in the socio demographic questionnaire (e.g., sex, civil and employment 
status) to obtain their frequency and percentage. In contrast, to describe the quantitative variables 
(e.g. age, age of diagnosis, FIQ and TSQM scores), the mean, standard deviation, minimum and 
maximum were obtained. 
To perform associations between variables, the ANOVA test was used to associate dependent and 
independent variables. The Pearson correlation was also used to correlate depended variables. A 
significance value of 5% (p <0,05) was always used.	
2.5 Ethic Concerns 
To certify the quality and integrity of the study and respect the confidentiality of the participants it 
was necessary to ensure that the study meet all ethical guidelines. The participant anonymity was 
taken into account and data were used only to statistical purposes. Before filling the questionnaire, 
the participant declares if wants to participate or not, with the filling of the informed consent. 
The Ethical committee of Escola Superior de Saúde approved the study, whose authorization is 
present in Attachment 7. 
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3. Results 
3.1 Part I – Socio-demographic characterization  
The sample was initially composed of a total of 187 individuals recruited through MYOS, FIBRO and 
APJOF associates. Out of 187, one of the individuals was excluded for not accepting to answer the 
questionnaire and another 9 were excluded for not having Portuguese nationality. The final sample 
was composed by 177 individuals. The socio-demographic characterization is described in the table 
below (table 1).  
The obtained sample was mostly female, with a percentage of 96,6% (n=171), while male 
participants represented only 3,4% of the sample (n = 6). 
The average age of the participants was 47,26±10.60 years, and regarding civil status, mostly were 
married (66,7%). 
Most of the participants were living in Portugal mainland (96,6%), without major differences 
between the three main regions: north, center and south, with only 6 individuals living in the islands: 
Azores or Madeira. 
Regarding academic education, most of the sample had a higher education degree (54,8%). And 
regarding employment status, the majority (75,1%) was working at the moment of the study 
enrolment.  
 
Table 1 - Socio demographic characterization: age, civil status, residence area, education and employment 
status * 
Variable Frequency (n) Percentage (%) 
Age   
20-29 years 10 5,6 
30-39 years 28 15,8 
40-49 years 68 38,4 
50-59 years 45 25,4 
60-69 years 23 13,0 
+ 70 years 2 1,1 
 
Civil Status 
  
Married 118 66,7 
Divorced 20 11,3 
Single 37 20,9 
Widower 2 1,1 
 
Residence Area 
  
Azores or Madeira 6 3,4 
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Centre 63 35,6 
North 50 28,2 
South 58 32,8 
 
Education 
  
4th Grade 9 5,1 
6th Grade 3 1,7 
9th Grade 17 9,6 
High School 51 28,8 
University 97 54,8 
 
Employment Status 
  
Not working 23 13,0 
Employed 133 75,1 
Student 1 0,6 
Retired 20 11,3 
                                                                           *note that an individual did not respond to his age. 
 
 
One of the questions answered in the first part of the questionnaire was about the time of FM 
diagnosis. The table below (Table 2) describes the time diagnosis was made, note that most 
respondents were diagnosed with FM less than 5 years ago (55,4%). Participants received 
diagnosis of FM at a mean age of 45,43± 10,10 years (note that an individual did not respond to his 
age). 
 
Table 2 - Time of FM diagnosis 
Variable Frequency (n) Percentage (%) 
Time of diagnosis   
< 5 years 98 55,4 
6-10 years 34 19,2 
11-15 years 26 14,7 
15-20 years 16 9,0 
+20 years 3 1,7 
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3.2 Part II – Fibromyalgia Impact Questionnaire (FIQ) 
Regarding the FIQ, the Portuguese version was applied to the studied sample (Rosado et al, 2006). 
This questionnaire, which allows us to understand the impact of FM on the quality of life of their 
patients, is divided into several sections, which allow do evaluate the impact of FM into different 
variables: depression, anxiety, stiffness, rested, fatigue, pain, do work, work missed, feel good and 
physical impairment. This score allows considering the impact of FM on a scale from 0 to 10. The 
different variables and their averages are described in the table 6 (Rosado et al., 2006). 
 
Table 3 - Average values of the different FIQ variables 
 
The table above presents the average values of the different variables found in FIQ. It was observed 
that there is a greater impact of the disease on fatigue, rest, stiffness and feeling good (7,99; 7,89; 
7,55 and 7,20, respectively). In contrast, the smallest values are found in work missed and physical 
impairment (3,64 and 4,12). 
However, the essential value of FIQ is obtained through a final formula that takes into account all the 
variables and allows to reach a value from 0 to 100. The average score obtained by a person with 
FM is 50, and a person where the disease has a major impact has a score around 70 (Rosado et al., 
2006). The average score obtained was 64,89 ± 15,92 (10-96). 
 
Regarding the relationship between the FIQ score and the number of drugs the individual takes and 
the time of diagnosis there is no statistically significant. However, there was a statistically 
significant association between age and FIQ value (p = 0,039), that means, this score increases with 
FIQ VARIABLES MEAN (SD) 
PHYSICAL IMPAIRMENT 4,12 (1,75) 
FEEL GOOD 7,20 (2,39) 
WORK MISSED 3,64 (3,45) 
DO WORK 6,75 (2,52) 
PAIN 6,78 (2,08) 
FATIGUE  7,99 (1,19) 
RESTED 7,89 (2,17) 
STIFFNESS 7,55 (2,14) 
ANXIETY 6,74 (2,68) 
DEPRESSION 6,23 (2,95) 
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age. Also, FIQ and the residence zone shows to be statically significant (p = 0,047), the value of FIQ 
are increased in individuals who live in Portugal mainland (Table 4). 
 
Table 4 - Association between FIQ and age, number of drugs, time of diagnosis and residence zone 
Variable Frequency (n) FIQ mean p value 
Age    
20-29 10 54,64 
0,039 
30-39 28 67,77 
40-49 68 65,21 
50-59 45 62,62 
60-69 23 66,84 
+70 2 90,60 
    
Number of Drugs    
1 28 65,15 
 
 
 
0,571 
2 55 61,32 
3 47 66,64 
4 24 65,84 
5 13 68,92 
6 6 69,73 
7 4 65,57  
Time of Diagnose    
< 5 99 62,97 
0,367 
6-10 33 65,72 
11-15 26 68,34 
15-20 16 69,80 
+20 3 63,03 
 
Residence Zone 
  
 
North 50 60,53 
0,047 
Centre 63 67,74 
South 58 66,41 
Azores/Madeira 6 56,63 
 
 
 
 
 
 
 32 
3.3 Part III- Pharmacotherapeutic Characterization 
In this section of the questionnaire, subjects were asked about the medication used for FM 
treatment. 
In this study, the average number of drugs used to manage FM is 2,85 (1-7). 
Regarding the medication used in FM, of 504 responses, the most common drugs were NSAIDs 
(17,7%), anxiolytic/benzodiazepines (16,9%) and cyclobenzaprine (FlexibanÒ) (15,5%). The less 
used drugs were milnacipran (IxelÒ) and bupropion (ElontrilÒ/WellbutrinÒ), also anyone respond 
pirlindole (Implementor®). The table below described the medication and respective frequencies.   
 
Table 5 - Described frequency and percentage of the drugs used to FM treatment* 
 
When asked about this being their first treatment, most respondents have already tried other 
medication: 67,2% (n=119). Regarding the reasons associated with the drug modification they 
included: lack of efficacy (45,4%), adverse reactions or others.  
The rheumatologist (n=113), followed by the family doctor(n=24), mainly prescribed FM drugs. 
 
 
 
DRUGS Frequency (n) Percentage (%) 
NSAIDS (e.g.  ibuprofen, naproxen, piroxicam) 89 17,7 
Anxiolytics/Benzodiazepines 
(e.g.lorazepam, alprazolam, clonazepam) 
85 16,9 
Cyclobenzaprine (Flexibanâ) 78 15,5 
Tramadol (Tramalâ) 59 11,7 
Duloxetine (Cymbaltaâ) 48 9,5 
Pregabalin (Lyricaâ) 42 8,3 
Fluoxetine (Prozacâ) 31 6,2 
Amitriptyline (ADTâ) 25 5,0 
Gabapentin (Neurontinâ) 21 4,2 
Venlafaxine (Efexorâ) 20 4,0 
Bupropion (Elontrilâ, Wellbutrinâ) 4 0,8 
Milnacipran (Ixelâ) 2 0,4 
* note that no one respond pirlindole (implementorâ) 
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3.4 Part IV- TSQM 1.4 
Concerning to TSQM, this questionnaire allows to understand the satisfaction with the medication 
currently using, in this case, to FM.  
With the TSQM is possible to find the individual opinion about the medication in four different ways: 
effectiveness, convenience, adverse effects and global satisfaction. The score ranges from 0 to 100, 
where higher scores indicate greater satisfaction (IQVIA, 2018). The means of each variable is 
described on table 6. It’s possible to observe a minor mean in the variable “effectiveness” and “global 
satisfaction”.  
 
Table 6 - Means of the TSQM variables: convenience, adverse effects, effectiveness and global satisfaction. 
TSQM variables Mean (SD) 
Convenience 67,07 (19,66) 
Adverse effects 67,59 (30,12) 
Effectiveness 45,01 (19,52) 
Global satisfaction 46,25 (22,23) 
 
 
Using Pearson's correlation coefficient, to relate de FIQ score and the four TSQM variables it’s 
possible to observed that the variable “convenience” and “adverse effects” had an inverse 
correlation with the FIQ score (r=-0,165, p=0,029 and r=-0,167, p=0,027, respectively), that means 
individuals with lower score on FIQ had a highest score on TSQM  (table 7). 
 
Table 7 - Pearson's correlation between FIQ and TSQM 
 FIQ  
 Pearson Correlation (r) p value 
Convenience -0,165 0,029 
Adverse Effects -0,167 0,027 
Effectiveness -0,098 0,196 
Global Satisfaction -0,093 0,212 
 
 
When observe the association between the TSQM values and the diagnosis time, it is possible to 
notice the variable “global satisfaction” was associated with diagnosis time (p = 0,025). Individuals 
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diagnosed longer (+20 years) have a lower score then the other groups. On other hand, adverse 
effects, effectiveness and convenience didn’t show to be statistically associated.  
When associate the number of drugs taken with the TSQM, only the variable adverse effects show 
a significant p value (p = 0,012). This means that individuals taking a larger number of drugs have a 
lower score on the adverse effect’s variable. The other TSQM variables were not statistically 
correlated. The table with the discriminated values can be found on the attachments (table 8 and 9 
on attachment 8). 
Regarding the association among the groups who are treated (yes) or not (no) with the drugs 
presented on the questionnaire and the mean scores of the TSQM variables, only the values of 
“global satisfaction” in duloxetine and fluoxetine are significant (p = 0,028 and p = 0,027). Individuals 
who take duloxetine present a higher score in global satisfaction, while individuals who take 
fluoxetine presents a lower value on global satisfaction. In addition, the variable “adverse effects” 
was statistically associated with the use of NSAIDs and tramadol (p = 0,025 and p = 0,003). In fact, 
individuals who take both drugs present a lower score on adverse effects. The described values can 
be observed on the attachment, table 10 (attachment 8). 
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4. Discussion 
 Socio-demographic characterization
This study intends to characterize the pharmacotherapeutic profile and impact of FM in a sample of 
Portuguese patients. In the study there was a clear prevalence of female patients (96,6%) compared 
to male (3,4%). Epidemiological studies in several countries around the world also show a higher 
prevalence of FM among females in relation to males (Branco et al., 2010; Marques et al., 2017; 
Neumann & Buskila, 2003).  This result may be related to the fact that chronic pain and depression 
is closely related to the female gender, and possibly modulated by estrogens. Pamuk et al., suggests 
a relationship between sex hormones and female prevalence; on their study, menopause women 
present more FM symptoms than premenopausal women (Maurer, Lissounov, Knezevic, Candido, & 
Knezevic, 2016; Pamuk & Çakir, 2005). In addition, Munce at al., indicates a bidirectional association 
with pain and depression: a vicious cycle that can be explained for low norepinephrine and serotonin, 
both related to depression and perception of pain (Munce & Stewart, 2007).  
FM can be developed at any age, however, is uncommon in young ages: only 10 participants 
presents an age less than 30 years. In mostly surveys the peak is around the middle age (30-50 
years) or after the 50’s. A study of Branco et al, shows that Portugal is the country with the youngest 
population (mean: 41 years), in the same study, the mean age in five European countries (France, 
Germany, Italy, Portugal, and Spain), is about 56 years old (Branco et al., 2010; Clauw, 2014; Queiroz, 
2013). The mean age of the participants in the present study was 47,26 years, which is in agreement 
with the existing literature (Branco et al., 2010; Clauw, 2014; Queiroz, 2013). 
Regarding to others social demographic aspects, the population was mainly married or single 
(66,7% and 20,9%, respectively). The literature is not clear about the marital status, with different 
authors finding higher frequency in widowed, divorced or married people (Queiroz, 2013). Opposing 
to existing literature, who relates the FM with low education (Bannwarth et al., 2009; Branco et al., 
2010; Mas et al., 2008), the majority of the sample of the present study had a college degree or 
completed high school (54,8% and 28,8%, respectively).  Mas et al., reports a lower prevalence of 
active work in FM patients. However, in this sample it’s possible to observe that 75,5% of the 
patients are currently working, who corresponds to a great majority of the sample (table 4) (Mas et 
al., 2008). Concerning the residence area, the literature is clear about the prevalence of FM in rural 
areas, however it’s not possible to demonstrate in the present study, since the questionnaire only 
refers to the different areas of Portugal, and there was no question addressing if it was a rural or 
urban area (Queiroz, 2013).  
Considering the diagnosis time, it was possible to observe that the bigger part of the sample was 
diagnosed less than five years (table 2), what gives a mean age of diagnosis of 45,43 years. 
Although FM was recognized as a rheumatic disease in 1992 by the World Health Organization, only 
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in 2016 the DGS recognized officially FM as a disease (Direção-Geral da Saúde, 2017). The 
relationship between this recent diagnosis time (<5 years) can be explained by the recent 
recognition of FM in Portugal. It must be noted that the year of the onset of symptoms was not 
asked, that means the individuals could already have the symptoms and have not yet been 
diagnosed.  
 
 Fibromyalgia Impact Questionnaire (FIQ) 
The literature agrees that FM is one of the most disabling disease. Mas et al., report that FM affects 
more quality of life than other rheumatic disease such as lupus erythematosus, RA, or ankylosing 
spondylitis (Mas et al., 2008). Verbunt et al., also points out that patients with FM have a lower 
quality of life than the general population. This decrease in quality life is related to the disability that 
patients feel in various aspects of daily life, such as functional capacity, professional life, quality of 
sleep or psychiatric disorders (Martinez et al., 1998; Mas et al., 2008; Verbunt et al., 2008). The FIQ, 
who was validated in 2006 for the Portuguese language, can help health professionals to study the 
functional capacity of a patient with FM and further help to manage the disease with the 
pharmacological and non-pharmacological treatment. In the present study, the mean of the 10 items 
who made the FIQ was analyzed (table 3): fatigue, rested and stiffness are the points with more 
impact in the participants, comparatively to work missed and physical impairment who presents the 
lowest mean score. Green et al., also indicates stiffens, pain muscle and awakening tired the 
symptoms more reported by FM patients (Green et al., 2005). The mean of the FIQ was 64,89, which 
indicates a relevant impact in quality life, once the score is above 50, and nearest 70, who indicates 
a severe impact. Martins et al., presents on his survey, also with Portuguese population, a mean 
score of 63,76 and also indicates a less score in missed work, as in the present study (Martins et al., 
n.d.) In the survey of Ruiz-Montero et al., the FIQ was applied in the three areas of Europe (North, 
South and Center). The south area corresponds to Spain where the FIQ presents the higher score: 
64,80, comparatively to the north area (62,85) and center area (60,87). In all three areas, the missed 
work dimension was the one with the lowest score. Is also observed that the population of the 
northern zone has less depression and anxiety prevalence (Ruiz-Montero et al., 2019).  
About the association between the FIQ score and some demographic variables (table 4), it can be 
concluded that age can be associated with the FIQ score. Older individuals have a higher FIQ score, 
this may be related to the fact that older people have more comorbidities, as other illnesses and 
greater pain sensitivity. Although, Green et al, didn’t report any relation between age and the FIQ 
score (p > 0,673) (Green et al., 2005 ).  
Regarding the area of residence, individuals living in the islands (Azores and Madeira) have a lowest 
FIQ score, this relationship may be associated with the more isolation who leads to less stress 
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(Clauw, 2014). However, the frequency of participants living in the islands is much smaller compared 
to those residing on the continent.  
 
Pharmacotherapeutic Characterization 
Given the substantial number of symptoms present in a patient with FM, it was not expected that 
only one drug will be effective in improving symptoms. Combination therapy is extremely common 
in these individuals and drugs are commonly prescribed according to patient’s needs. Robinson et 
al., state that over 75% of the FM population takes two or more drugs to treat the disease (Robinson 
et al., 2013). The mean of drugs used to manage FM in this sample was 2,85; with a maximum of 
seven drugs and a minimum of one. 
Considering the treatment to manage FM, is important to highlight that there’s no drug approved to 
FM in Portugal or any country of the Europe, all the prescribed drugs are off-label (Chinn et al., 2016). 
As also said before, FDA approves three drugs: pregabalin, duloxetine and milnacipran, however 
TCA drugs are also prescribed and in many cases as a first line therapy (Robinson et al., 2013).  In the 
present study it’s possible to observe that NSAIDs and anxiolytic drugs are the most common drugs 
used for FM patients (table 5). Regarding to NSAIDs, several studies discourage the use of these 
drugs due to its peripheral action, and chronic use who can lead to harmful adverse effects. However, 
the high frequency of their use in this study can be explained by the easy access, since some of them 
are over the counter drugs (Green et al., 2005; Kia & Choy, 2017; Macfarlane et al., 2017; Robinson 
et al., 2013; Schmidt-Wilcke & Clauw, 2011). Anxiolytic drugs are the second most used drugs in the 
study; however, this group is not clearly associated with an improvement in pain. In fact, its use 
might be correlated with the effect in sleep disorders, one of the most common symptoms in FM. 
Like NSAIDS, this group in not recommended to manage FM for EULAR and Scientific Medical 
Societies in Germany (AWMF), due to his addiction effect (Kia & Choy, 2017; Schmidt-Wilcke & 
Clauw, 2011)Tramadol (Tramal®), an opioid drug, but also a reuptake inhibitor of serotonin, also 
presents a high frequency use in this study (11,7%). However, tramadol use in FM is controverse: 
while EULAR and Canada guideline recommend is use, AWMF don’t recommend is use due to lack 
of solid data (Kia & Choy, 2017). 
Cyclobenzaprine (Flexiban®), one of the drug in the ATC group, is also one the most used drugs to 
manage FM (15,5%), is not only efficient in improvement pain but also in fatigue and sleep 
disturbance due to his muscle relaxant action, and it’s recommend by EULAR (Kia & Choy, 2017; 
Schmidt-Wilcke & Clauw, 2011). Amitriptyline (ADT®), is also recommend by AWMF for first line 
therapy, and in low doses by EULAR; however only presents a 5% of response in the study (Kia & 
Choy, 2017). 
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Regarding the drugs approved by FDA, Pregabalin (Lyrica®) and Duloxetine (Cymbalta ®), present 
a considerable frequency (n=42 and n=48, respectively) comparatively with the study of Green et al 
(Green et al., 2005). Pregabalin is recommended by EULAR and AWMF, when the treatment with 
amitriptyline (ADT®) is not efficient (Kia & Choy, 2017). Duloxetine (Cymbalta ®), has a higher 
frequency of responses in the study (n=48): the AWMF recommend this drug when a depression 
disorder his associate to FM due to his effect on serotonin (Kia & Choy, 2017; Macfarlane et al., 2017), 
and this comorbidity might explain is elevated prescription.  In contrast, only two individuals actually 
take milnacipran (Ixel®) for FM management, a drug also approved by FDA.  Although pirlindole 
(Implementor ®) shows better results comparatively to placebo, there was no reference to is use in 
the study. This result can be explained for the fact that IMAO drugs have harmful effects when 
interacts with other medication such as SSRI (Macfarlane et al., 2017).  
Patients with FM report high rates of change increase or discontinuation of therapy associated with 
lack of efficacy or adverse effects, which are not well tolerated by patients. In this study, a large part 
of the sample (67,2%) have already been treated with other drugs, being the most pointed reason 
for the change the lack of effectiveness. This result is in agreement with the study of  Robinson et al. 
(Robinson et al., 2013).   
 
TSQM  
The TSQM is a tool which allows to evaluate patient's experience and satisfaction with the 
medication they take. This tool score from 0 to 100, where higher scores indicate a better 
satisfaction. In the present study is possible to observe that the effectiveness and global 
satisfaction present a lower score (45,01 and 46,25). The low effectiveness score can be supported 
for the diagnosis time (the major part of the sample was diagnosed under 5 years), which means the 
complete control of the disease was not accomplish yet. In the survey of Lauche et al., it’s possible 
to observe that people who have been diagnosed longer has higher satisfaction in general, who 
contraries the results found in this study. However, the large percentage of the sample in the study 
of Lauche et al. shows a low to moderate satisfaction to the treatment (Lauche et al., 2013).  
Regarding the relation between FIQ and TSQM, the convenience and the adverse effects appeared 
to be statistically related. These two variables present an inverse correlation: individuals with a 
lower score of FIQ present a higher score in TSQM. Individuals who have a lowest FIQ score are more 
satisfied with the adverse effects (don’t have significant adverse effects) and with the convenient 
(it’s easy to take the medication). A lower FIQ score, means that the disease has a minor impact in 
the life of a FM patient: the medication is effective, has no adverse effects and is convenient to take 
(Lauche et al., 2013).  
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Nöller et al., state that people diagnosed longer have a higher satisfaction with treatment, which may 
be related to a mental adjustment made to the disease, in contrast, when observed the relationship 
between the TSQM and the time of diagnosis, in this study, is possible to observe that the individuals 
diagnosed longer present the lowest TSQM value on the global satisfaction dimension, which 
translates into non-satisfaction of the treatment (Nöller & Sprott, 2003). In other hand, when 
observed the association between the TSQM and number of drugs, patients who take more drugs 
had a lower score in adverse effects dimension of TSQM. The reason for this result may be related 
to the fact that the patient experienced adverse effects, possibly related to drug interactions (Clauw, 
2014). 
When compared the score of TSQM with the different drugs, it can be noted that the group taking 
NSAIDs and Tramadol (Tramal ®) has a lower adverse effects score, which may be related to the 
side effects experienced when NSAIDs when used chronically, such as gastrointestinal problems 
and in tramadol’s case, tolerance and withdrawal symptoms (Clauw, 2014). Other significant value 
was observed in the dimensions global satisfaction of the TSQM and individuals that take fluoxetine 
(yes) present a lower score, in other hand, individuals who take duloxetine (yes) had a higher score 
in global satisfaction. One explanation for these results could be that NRIS, such as duloxetine, have 
an improved effect on pain as they are not only serotonin inhibitors such as fluoxetine, an SSRI, but 
also norepinephrine, both involved not only in depression but also in pain inhibition (Clauw, 2014). 
 
4.1 Limitations 
However, despite the promising results reported here, some points should be highlighted. One 
limitation of the study was the asymmetry of the sample regarding gender. Although the prevalence 
of FM is higher in women, men are also affected and are not representative in the sample, which 
does not allow to have in-depth knowledge about the male reality. Also, the fact that the 
questionnaire was autofill, leads each individual to interpret certain questions in their own way. 
Additionally, non-pharmacological treatment, the existence of other diseases, the age of onset of 
symptoms, or if lives in a rural or urban area where not inquired to the patients. It is also noteworthy 
that the perception of the impact of the disease and the treatment performed may change over time, 
which could be solved with a longitudinal study. Another limitation of the study is not being clear 
which criteria was used to diagnose the disease.  
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5. Conclusion and future perspectives 
In this study, it was possible to observe that FM had a negative impact on life of a sample of 
Portuguese patients. This impact can range from getting out of bed to work. The disease can affect 
patient’s functional capacity, not only physically but also psychologically. This influence can 
probably be due to is correlation with disorders like depression and anxiety. In our sample, the 
impact of FM was associated with age, likely due to the presence of other comorbidities.  
Drug treatment was found to have a positive impact on patient’s life. In fact, it was observed that the 
correct treatment is essential to improve the symptoms, with a consequent improvement in health 
conditions and functional capacity. FM patients tend to take two or more drugs, and the most used 
in the sample were NSAIDs and anxiolytics. However, and accordingly to different guidelines, they 
are not the most indicated drugs for FM treatment. The referenced medication to treat FM, such as 
depressants (TCA, SSIR and SNIR) and anticonvulsants were found to have a lower frequency in this 
sample.  
Treatment satisfaction is essential in FM patient. The two most important factors affecting 
treatment satisfaction were the presence of adverse effects and drug efficacy, which are also 
correlated with the drug class.  
The request for social support and adaptation in a professional and familiar life must also be 
addressed, not only to improve the well-being of FM patients, but also the ones around them.  
Further research is needed to unravel effective therapies that can ameliorating the various 
symptoms of FM, with minimal adverse effects, in order to ensure treatment adherence and further 
improve patient’s quality of life.  
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7. Attachments 
Attachment 1 – Autorizations MYOS and APJOF 
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Attachment 2 - Socio-demographic characterization 
 
  
1º Parte  - Questionário Sociodemográfico  
Instruções: Deverá assinalar com um (X) a resposta correspondente à sua situação.  
 
Sexo: Feminino ____                                                                    Masculino ____ 
 
Idade: __________ 
 
Estado Civil: 
Solteiro/a _______ 
Casado/a _______ 
Divorciado/a _______ 
Viúvo/a _______ 
 
Zona de residência: 
Região Norte _______ 
Região Centro _______ 
Região Sul _______ 
Açores/Madeira_______ 
 
Habilitações Literárias:  
4º ano _______ 
6º ano_______ 
9º ano _______ 
12º ano _______ 
Ensino Superior _______ 
 
Situação Profissional: 
Empregado/a: _________  
Desempregado/a: ____________  
Reformado/a: _____________  
Estudante: _____________  
 
Há quanto tempo foi diagnosticado com a doença?  
____________ ano/s. 
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Attachment 3 – Fibromyalgia Impact Questionnaire Portuguese Version (FIQ-P) 
 
2ª Parte - Fibromyalgia Impact Questionnaire (versão portuguesa) - FIQ-P 
 
INSTRUÇÕES: Nas perguntas 1 a 11 por favor faça um círculo no número que, em relação à última 
semana, melhor descreve a maneira como, em geral, foi capaz de executar as tarefas indicadas. Se 
habitualmente não faz uma dessas tarefas risque essa pergunta.  
 
Foi capaz de: Sempre Quase 
sempre 
Quase   
nunca 
Nunca 
1.  Ir às compras? 0 1 2 3 
2. Tratar da roupa na máquina de 
lavar/secar? 
0 1 2 3 
3. Cozinhar? 0 1 2 3 
4. Lavar louça à mão? 0 1 2 3 
5. Aspirar a casa? 0 1 2 3 
6. Fazer as camas? 0 1 2 3 
7. Andar vários quarteirões (200 a 
500 metros)? 
0 1 2 3 
8. Visitar a família ou os amigos? 0 1 2 3 
9. Tratar das plantas ou praticar o 
seu passatempo? 
0 1 2 3 
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10. Se deslocar, no seu próprio carro 
ou em transportes públicos? 
0 1 2 3 
11. Subir as escadas? 0 1 2 3 
 
12. Na última semana, em quantos dias se sentiu bem? 
0 1 2 3 4 5 6 7 
        
13. Na última semana, quantos dias faltou ao trabalho e/ou não realizou as tarefas 
domésticas, devido à fibromialgia? 
0 1 2 3 4 5 6 7 
 
INSTRUÇÕES: Nas perguntas que se seguem, assinale um ponto na linha que melhor 
indica o modo como, em geral, se sentiu na última semana. 
14. Nos dias que trabalhou, quanto é que a sua doença – Fibromialgia - interferiu no seu  
trabalho?  
       • ___ |___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
15.  Que intensidade teve a sua dor? 
       • ___ |___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
16.  Que cansaço sentiu? 
       • ___ |___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
17. Como se sentiu quando se levantava de manhã? 
      • ___ |___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
 
Trabalhei sem 
problemas       Tive grande dificuldade no trabalho 
NNão tive dor Tive dor intensa 
Não senti cansaço       Senti um cansaço enorme 
Acordei bem disposta Acordei muito cansada 
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18.  Que rigidez sentiu? 
    • ___ |___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
19. Sentiu-se nervosa ou ansiosa? 
 
        •___ | ___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
20.  Sentiu-se triste ou deprimida? 
            
 
          •___ | ___ | ___ | ___ | ___ |___ | ___ | ___ | ___ | ___ | ___ • 
Não tive rigidez Senti muita rigidez 
Não tive ansiedade Senti-me muito ansiosa 
Não me senti deprimida Senti-me muito 
deprimida 
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Attachment 4 - Pharmacotherapeutic characterization 
 
 
3ª parte – Caracterização farmacoterapêutica  
Instruções: Deverá assinalar com um (X) a resposta correspondente à sua situação.  
 
1. Assinale qual ou quais o/os medicamento/os que está a tomar, para o tratamento 
da fibromialgia (pode assinalar mais que uma opção).  
 
Amitriptilina (ADT£)_______ 
 
Ciclobenzapirina (Flexiban£)_______ 
 
Fluoxetina (Prozac£)_______ 
 
Duloxetina (Cymbalta£)_______ 
 
Milnaciprano (Ixel£)_______ 
 
Gabapentina (Neurontin£)_______ 
 
Pregabalina (Lyrica£)_______ 
 
Tramadol (Tramal£)_______ 
 
Pirlindole (Implementor£)_______ 
 
Venlafaxina (Efexor£)_______ 
 
Bupropiom (Elontril£, Wellbutrin£)_______ 
 
Anti-inflamatórios não esteroides (ibuprofeno, naproxeno, piroxicam) _______ 
 
Ansiolíticos (lorazepam, alprazolam, clonazepam) _______ 
 
Outros (indique qual/quais) _________________________________________ 
______________________________________________________________.  
 
2. É o primeiro tratamento que realiza para a terapêutica da doença? 
Sim_______ (Passe diretamente para a pergunta 5) 
Não_______ 
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3. Indique quais os medicamentos que tomou no passado, para o tratamento da 
fibromialgia. 
________________________________________________________________
________________________________________________________________ 
 
4. Qual o motivo que levou à alteração da medicação? 
Efeitos adversos_______ 
Falta de eficácia_______ 
Outro _______ Qual? ______________________________________________ 
 
5. Quem foi o prescritor do/s medicamento/s que toma atualmente para a 
fibromialgia? 
Médico de família_______ 
Serviço de Urgências_______ 
Reumatologista_______ 
Outro _______ Qual? ______________________________________________ 
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Attachment 5 – TSQM V 1.4 Portuguese 
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TSQM (versão 1.4) 
 
Questionário sobre Satisfação com o Medicamento  
(versão portuguesa do TSQM) 
Instruções: Por favor dedique algum tempo a pensar sobre o seu nível de 
satisfação ou insatisfação com o medicamento que se encontra a tomar neste 
ensaio clínico. Estamos interessados na sua avaliação da eficácia, dos efeitos 
secundários e da conveniência do medicamento durante as últimas duas ou três 
semanas ou desde a última vez que usou o medicamento. Para cada questão, 
marque somente a resposta que melhor corresponde à sua experiência. 
1. Até que ponto está satisfeito ou insatisfeito com a eficácia do medicamento usado em evitar ou 
tratar a sua doença? 
 
□1   Extremamente insatisfeito 
□2   Muito insatisfeito 
□3   Insatisfeito 
□4   Mais ou menos satisfeito 
□5   Satisfeito 
□6   Muito satisfeito 
□7   Extremamente satisfeito 
 
2. Até que ponto está satisfeito ou insatisfeito com a maneira como o medicamento alivia os seus 
sintomas? 
 
□1   Extremamente insatisfeito 
□2   Muito insatisfeito 
□3   Insatisfeito 
□4   Mais ou menos satisfeito 
□5   Satisfeito 
□6   Muito satisfeito 
□7   Extremamente satisfeito 
 
3. Até que ponto está satisfeito ou insatisfeito com o tempo que o medicamento demora até 
começar a fazer efeito? 
 
□1   Extremamente insatisfeito 
□2   Muito insatisfeito 
□3   Insatisfeito 
□4   Mais ou menos satisfeito 
□5   Satisfeito 
□6   Muito satisfeito 
□7   Extremamente satisfeito 
 
4.  Sente algum efeito secundário (colateral) causado por este medicamento? 
 
□1   Sim 
□0   Não  (Neste caso, passe para a Pergunta 9.) 
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5. Até que ponto são incómodos os efeitos secundários do medicamento que se encontra a tomar 
para tratar a sua doença? 
 
□1   Extremamente incómodos 
□2   Muito incómodos 
□3   Mais ou menos incómodos 
□4   Um pouco incómodos 
□5   Não são incómodos 
 
6. Até que ponto os efeitos secundários interferem com a sua saúde física e a sua capacidade de 
viver uma vida normal (isto é, força, nível de energia, etc.)? 
 
□1   Muitíssimo 
□2   Muito 
□3   Mais ou menos 
□4   Muito pouco 
□5   Nada 
 
7. Até que ponto os efeitos secundários interferem com as suas funções mentais (por exemplo, 
capacidade de pensar com clareza, permanecer acordado, etc.)?  
 
□1   Muitíssimo 
□2   Muito 
□3   Mais ou menos 
□4   Muito pouco 
□5   Nada 
 
8. Até que ponto os efeitos secundários do medicamento têm afectado a sua satisfação geral com 
o medicamento? 
 
□1   Muitíssimo 
□2   Muito 
□3   Mais ou menos 
□4   Muito pouco 
□5   Nada 
 
9. Qual é o grau de facilidade ou dificuldade em utilizar o medicamento na sua forma actual de 
administração? 
 
□1   Extremamente difícil 
□2   Muito difícil 
□3   Difícil 
□4   Mais ou menos fácil 
□5   Fácil 
□6   Muito fácil 
□7   Extremamente fácil 
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10. Qual é o grau de facilidade ou dificuldade em planear cada uso do medicamento? 
□1   Extremamente difícil 
□2   Muito difícil 
□3   Difícil 
□4   Mais ou menos fácil 
□5   Fácil 
□6   Muito fácil 
□7   Extremamente fácil 
 
11. Até que ponto é conveniente ou inconveniente tomar o medicamento segundo as instruções? 
□1   Extremamente inconveniente 
□2   Muito inconveniente 
□3   Inconveniente 
□4   Mais ou menos conveniente 
□5   Conveniente 
□6   Muito conveniente 
□7   Extremamente conveniente 
 
12. De modo geral, até que ponto está confiante de que tomar este medicamento é bom para si? 
□1   Nada confiante 
□2   Um pouco confiante 
□3   Mais ou menos confiante 
□4   Muito confiante 
□5   Extremamente confiante 
 
13. Até que ponto está convencido de que os pontos positivos do seu medicamento compensam 
os pontos negativos? 
□1   Nada convencido 
□2   Um pouco convencido 
□3   Mais ou menos convencido 
□4   Muito convencido 
□5   Extremamente convencido 
 
14. Levando tudo em conta, até que ponto se sente satisfeito ou insatisfeito com este 
medicamento? 
□1   Extremamente insatisfeito 
□2   Muito insatisfeito 
□3   Insatisfeito 
□4   Mais ou menos satisfeito 
□5   Satisfeito 
□6   Muito satisfeito 
□7   Extremamente satisfeito 
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Attachment 6 – IQVIA authorization 
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Attachment 7- Ethics Reponse 
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Attachment 8 – Results 
Table 8 - Association TSQM variables and time of diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Time of diagnosis Mean p value 
Global Satisfaction 
< 5 years 44,3723 
0,025 
6-10 years 52,5974 
11-15 years 45,0549 
16-20 years 52,6786 
+ 20 years 14,2857 
Effectiveness 
< 5 years 43,6027 
0,351 
6-10 years 49,4949 
11-15 years 43,8034 
16-20 years 48,9583 
+ 20 years 31,4815 
Adverse Effects 
<5 years 69,9705 
0,641 
6-10 years 64,0783 
11-15 years 62,1795 
16-20 years 71,0938 
+ 20 years  56,2500 
Convenience 
< 5 years 68,5746 
0,213 
6-10 years 67,6768 
11-15 years 64,5299 
16-20 years 65,2778 
+ 20 years 42,5926 
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Table 9 -  Association TSQM variables and number of drugs 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Nr of drugs Mean p  value 
Global 
Satisfaction 
1 41,8367 
0,300 
2 50,0000 
3 48,6322 
4 46,1310 
5 38,4615 
6 32,1429 
7 44,6429 
Effectiveness 1 43,0556 
0,666 
2 48,7879 
3 44,2080 
4 44,9074 
5 38,8889 
6 39,8148 
 7 44,4444  
Adverse Effects 1 70,4613 
0,012 
2 75,2652 
3 66,4007 
4 69,5313 
5 46,1538 
6 51,0417 
 7 39,0625 
Convenience 1 62,3016 
0,413 
2 70,1010 
3 69,9764 
4 63,1944 
5 66,2393 
6 62,0370 
7 58,3333 
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Table 10- Association between TSQM variables and medication* 
 
         DRUGS 
 
 
Global Satisfaction Effectiveness Adverse Effects Convenience 
Mean p value Mean p value Mean p value Mean p value 
DULOXETINE 
 (CYMBALTA®) 
No 44,020 0,028 43,928 0,228 67,555 0,976 65,848 0,174 
Yes 52,232 47,917 67,708 70,370 
FLUOXETINE  
(PROZAC®) 
No 47,945 0,027 45,358 0,608 68,721 0,282 67,884 0,235 
Yes 38,249 43,370 62,298 63,261 
CYCLOBENZAPRINE 
(FLEXIBAN®) 
No 47,114 0,569 45,061 0,968 68,940 0,506 65,881 0,364 
Yes 45,146 44,943 65,891 65,590 
ANXIOLYTICS (E.G. LORAZEPAM, 
ALPRAZOLAM, CLONAZEPAM) 
No 47,826 0,327 46,496 0,293 68,682 0,619 67,150 0,958 
Yes 44,538 43,399 66,421 66,993 
NSAID (E.G. IBUPROFENO, 
NAPROXENO, PIROXICAM) 
No 48,458 0,189 47,474 0,095 72,680 0,025 68,308 0,408 
Yes 44,061 42,572 62,570 65,855 
BUPROPION 
(ELONTRIL®/WELLBUTRIN®) 
No 46,160 0,743 44,926 0,710 67,245 0,308 67,084 0,967 
Yes 50,000 48,611 82,812 66,666 
VENLAFAXINE (EFEXOR®) No 45,723 0,770 44,869 0,071 68,033 0,291 66,737 0,408 
Yes 50,357 46,111 64,167 69,722 
GABAPENTIN (NEURONTIN®) No 46,062 0,764 45,157 0,785 67,161 0,601 66,987 0,872 
Yes 47,619 43,915 70,833 67,725 
TRAMADOL (TRAMAL®) No 47,820 0,184 45,386 0,718 72,316 0,003 68,927 0,076 
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Yes 43,099 44,256 58,167 63,371 
PREGABALIN (LYRICA ®) No 46,455 0,824 45,720 0,387 69,120 0,229 67,325 0,762 
Yes 45,578 42,724 62,698 66,270 
MILNACIPRAN (IXEL ®) No  46,244 0,991 45,079 0,657 68,012 0,086 67,079 0,977 
Yes 46,429 38,889 31,250 66,666 
AMITRIPTYLINE (ADT®) No 46,053 0,775 44,700 0,605 69,133 0,094 67,727 0,278 
Yes 47,429 46,889 58,250 63,111 
*note that no one respond pirlindole (implementor®).  
 
 
 
 
 
